Almirall S.A. | Income Statement

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
692,891.00
786,396.00
684,985.00
764,361.00
639,381.00
756,934
Cost of Goods Sold (COGS) incl. D&A
476,613.00
512,359.00
413,418.00
490,836.00
480,737.00
435,873
Gross Income
216,278.00
274,037.00
271,567.00
273,525.00
158,644.00
321,061
SG&A Expense
328,246.00
318,670.00
226,981.00
270,481.00
259,323.00
250,375
EBIT
116,848.00
55,952.00
40,002.00
2,120.00
100,197.00
55,522
Unusual Expense
84,856.00
99,524.00
19,286.00
18,709.00
277,991.00
29,492
Non Operating Income/Expense
115,331.00
640,815.00
110,924.00
128,121.00
60,734.00
2,538
Interest Expense
3,814.00
4,128.00
416.00
20,143.00
5,215.00
7,944
Pretax Income
89,729.00
481,977.00
172,636.00
92,637.00
321,063.00
74,974
Income Tax
56,012.00
33,548.00
40,810.00
17,158.00
17,102.00
2,700
Consolidated Net Income
33,717.00
448,429.00
131,826.00
75,479.00
303,961.00
77,674
Net Income
33,717.00
448,429.00
131,826.00
75,479.00
303,961.00
77,674
Net Income After Extraordinaries
33,717.00
448,429.00
131,826.00
75,479.00
303,961.00
77,674
Net Income Available to Common
33,717.00
448,429.00
131,826.00
75,479.00
303,961.00
77,674
EPS (Basic)
0.19
2.59
0.76
0.44
1.76
0.45
Basic Shares Outstanding
172,984.00
172,951.00
172,951.00
172,951.00
172,951.00
173,446
EPS (Diluted)
0.19
2.59
0.76
0.44
1.76
0.45
Diluted Shares Outstanding
172,984.00
172,951.00
172,951.00
172,951.00
172,951.00
173,446
EBITDA
47,403.00
28,757.00
114,252.00
102,416.00
3,463.00
145,702
Other Operating Expense
4,880.00
11,319.00
4,584.00
924.00
482.00
15,164
Non-Operating Interest Income
458.00
766.00
2,840.00
1,248.00
1,606.00
442

About Almirall

View Profile
Address
Ronda General Mitre, 151
Barcelona Catalonia 08022
Spain
Employees -
Website http://www.almirall.com
Updated 07/08/2019
Almirall SA engages in the development, manufacture, storage, commercialization and sale of pharmaceutical and cosmetic products, as well as of the raw materials used in production. The company operates through the following segments: Marketing through Own Network, Marketing by Licensees, Research and Development Activity, Therapeutic Area of Dermatology in the United States, and Corporate Management and Results not assigned to Other Segments. Its products include treatments for respiratory, autoimmune, dermatological and gastrointestinal diseases.